Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Vaxelis (V419) in Infants
NCT01337167Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2011
- Primary completion
- May 2013
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 3, randomised, open-label trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen at Month 7, Percentage of Participants Responding to Hepatitis B Surface Antigen at Month 7 and 5 more. Started Apr 2011; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on NCT01337167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01337167.